[Differential indications for induction therapy of non-small-cell lung tumors].
Induction chemotherapy and induction chemo-radiotherapy have shown their efficiency and feasibility in many phase-II studies and have profen superior to operation alone in stage IIIa of NSCLC in several phase-III studies. Therefore it is justified to recommend this multimodal therapy in stage IIIa N2 disease within clinical studies. However, it is currently not justified to present this multimodal treatment modality as a generally agreed standard.
Drings
P
P
Abteilung Innere Medizin-Onkologie, Thoraxklinik Heidelberg gGmbH, Heidelberg. prof.drings@t-online.de
Manegold
C
C
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011013:Pneumonectomy; D015996:Survival Rate; D016896:Treatment Outcome
Differentialindikation zur Induktionstherapie bei nicht-kleinzelligen Lungentumoren.